35 results on '"Hamm C"'
Search Results
2. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome
- Author
-
Nef, H. M., primary, Wiebe, J., additional, Schmidt, G., additional, Möllmann, H., additional, Boeder, N. F., additional, Dörr, O., additional, Bauer, T., additional, Blachutzik, F., additional, Liebetrau, C., additional, Elsässer, A., additional, Foin, N., additional, and Hamm, C. W., additional
- Published
- 2019
- Full Text
- View/download PDF
3. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.
- Author
-
Nef, H. M., Wiebe, J., Schmidt, G., Möllmann, H., Boeder, N. F., Dörr, O., Bauer, T., Blachutzik, F., Liebetrau, C., Elsässer, A., Foin, N., and Hamm, C. W.
- Subjects
ACUTE coronary syndrome ,MYOCARDIAL infarction ,ANGINA pectoris ,EVEROLIMUS ,INTRAVASCULAR ultrasonography ,BIOABSORBABLE implants ,DRUG-eluting stents - Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
4. Leadless pacing
- Author
-
Sperzel, J., primary, Hamm, C., additional, and Hain, A., additional
- Published
- 2018
- Full Text
- View/download PDF
5. Herzklappenerkrankungen
- Author
-
Gaede, L., primary, Blumenstein, J., additional, Liebetrau, C., additional, Dörr, O., additional, Kim, W.-K., additional, Hamm, C., additional, Elsässer, A., additional, Nef, H., additional, and Möllmann, H., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Management des akuten Koronarsyndroms ohne ST-Strecken-Hebung
- Author
-
Liebetrau, C., primary and Hamm, C. W., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Herzklappenerkrankungen.
- Author
-
Gaede, L., Blumenstein, J., Liebetrau, C., Dörr, O., Kim, W.-K., Hamm, C., Elsässer, A., Nef, H., and Möllmann, H.
- Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
8. Temporal trends in transcatheter and surgical aortic valve replacement
- Author
-
Gaede, L., primary, Kim, W.-K., additional, Blumenstein, J., additional, Liebetrau, C., additional, Dörr, O., additional, Nef, H., additional, Hamm, C., additional, Walther, T., additional, Achenbach, S., additional, Elsässer, A., additional, and Möllmann, H., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Computertomographie bei Patienten mit stabiler Angina Pectoris
- Author
-
Renker, M., primary, Schoepf, U. J., additional, Becher, T., additional, Krampulz, N., additional, Kim, W., additional, Rolf, A., additional, Möllmann, H., additional, Hamm, C. W., additional, Henzler, T., additional, Borggrefe, M., additional, Akin, I., additional, and Baumann, S., additional
- Published
- 2016
- Full Text
- View/download PDF
10. Akutes Koronarsyndrom und antithrombozytäre Therapie
- Author
-
Bauer, T., primary and Hamm, C., additional
- Published
- 2014
- Full Text
- View/download PDF
11. Temporal trends in transcatheter and surgical aortic valve replacement.
- Author
-
Gaede, L., Kim, W.-K., Blumenstein, J., Liebetrau, C., Dörr, O., Nef, H., Hamm, C., Walther, T., Achenbach, S., Elsässer, A., and Möllmann, H.
- Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
12. Computertomographie bei Patienten mit stabiler Angina Pectoris.
- Author
-
Renker, M., Schoepf, U., Becher, T., Krampulz, N., Kim, W., Rolf, A., Möllmann, H., Hamm, C., Henzler, T., Borggrefe, M., Akin, I., and Baumann, S.
- Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
13. “Full bioresorbable jacket”
- Author
-
Dörr, O., primary, Liebetrau, C., additional, Hecker, F., additional, Wiebe, J., additional, Möllmann, H., additional, Hamm, C., additional, and Nef, H., additional
- Published
- 2013
- Full Text
- View/download PDF
14. Myokardrevaskularisation
- Author
-
Möllmann, H., primary, Szardien, S., additional, Kempfert, J., additional, Nef, H., additional, Liebetrau, C., additional, Walther, T., additional, and Hamm, C., additional
- Published
- 2013
- Full Text
- View/download PDF
15. Neue Antikoagulanzien bei Vorhofflimmern
- Author
-
Madlener, K., primary and Hamm, C., additional
- Published
- 2012
- Full Text
- View/download PDF
16. Rotablation: Technik, Indikation, Ergebnisse
- Author
-
Dill, T., primary and Hamm, C. W., additional
- Published
- 1997
- Full Text
- View/download PDF
17. 'Full bioresorbable jacket'.
- Author
-
Dörr, O., Liebetrau, C., Hecker, F., Wiebe, J., Möllmann, H., Hamm, C., and Nef, H.
- Published
- 2015
- Full Text
- View/download PDF
18. [Heart valve disesases : How sufficient is the knowledge of the German population?]
- Author
-
Gaede L, Blumenstein J, Liebetrau C, Dörr O, Kim WK, Hamm C, Elsässer A, Nef H, and Möllmann H
- Subjects
- Aortic Valve, Cardiac Catheterization, Germany, Humans, Middle Aged, Treatment Outcome, Aortic Valve Stenosis, Health Knowledge, Attitudes, Practice, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Transcatheter Aortic Valve Replacement
- Abstract
To evaluate the awareness and knowledge of the German population regarding diseases in general, a survey of 1446 people aged 60 years or older was conducted in 14 German towns. The focus was on heart valve diseases with special emphasis on aortic valve stenosis (AS). While cancer was the disease that respondents were most concerned about (25.2%), only 3.3% were concerned about heart valve diseases. In this respect, the knowledge was broadly limited: only 7.4% of participants claimed to have some familiarity with heart valve diseases and only 12.5% could correctly describe the symptoms of AS. Even so, 35.0% of the participants could correctly name the number of human heart valves, 71.6% knew at least one therapy option for AS and 30.6% were familiar with transcatheter aortic valve implantation (TAVI). After providing a brief clarification of the prevalence, symptoms and course of AS, 45.6% of respondents were more concerned about the condition, 15.7% wanted to know more about the symptoms of AS and 4.7% even recognized the typical symptoms in themselves. Most of the participants would like to seek more information preferably in discussion with a specialist physician (77.2%), with their general practitioner (43.2%) or using the internet (29.7%). Despite its high prevalence, high morbidity and mortality, the vast majority of the German population were neither concerned nor fully aware of treatment options for AS. There is a strong case for public awareness campaigns that provide better knowledge of AS, and support check-ups that enable timely treatment and the avoidance of unnecessary hospitalization and death.
- Published
- 2019
- Full Text
- View/download PDF
19. [MINOCA-myocardial infarction with non-obstructive coronary arteries].
- Author
-
Hamm C and Hamm CW
- Subjects
- Coronary Angiography, Coronary Vessels, Female, Humans, Male, Coronary Artery Disease, Myocardial Infarction, Takotsubo Cardiomyopathy
- Abstract
In recent years it has been observed with increasing interest that there is a group of patients with electrocardiographic and laboratory features of myocardial infarction (MI) but no obstructive coronary artery disease (<50% diameter stenosis). For this entity the term myocardial infarction with non-obstructive coronary arteries (MINOCA) has been coined. The prevalence of MINOCA is estimated to be 6-9% among patients diagnosed with MI and it is more common in women than men as well as in patients presenting with NSTEMI than in those presenting with STEMI. The MINOCA is a working diagnosis that requires a further diagnostic work-up by invasive techniques, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) or non-invasive imaging with cardiac magnetic resonance imaging (CMRI). When it is ascertained that obstructive coronary artery disease has not been inadvertently overlooked, other coronary disorders, such as plaque rupture or erosion, thrombosis, dissection, spasms or microvascular dysfunction should be evaluated. Furthermore, myocarditis or tako-tsubo cardiomyopathy should be excluded by CMRI as non-coronary causes. The further treatment and prognosis of patients with MINOCA depend on the underlying cause and the final diagnosis.
- Published
- 2018
- Full Text
- View/download PDF
20. [Management of acute coronary syndrome without ST-segment elevation].
- Author
-
Liebetrau C and Hamm CW
- Subjects
- Acute Coronary Syndrome blood, Biomarkers blood, Diagnosis, Differential, Evidence-Based Medicine, Humans, ST Elevation Myocardial Infarction blood, ST Elevation Myocardial Infarction complications, ST Elevation Myocardial Infarction diagnosis, Treatment Outcome, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome therapy, Critical Care methods, Myocardial Revascularization methods, Troponin I blood, Troponin T blood
- Abstract
Acute coronary syndrome without persistent ST-segment elevation (non-ST segment elevation myocardial infarction and instable angina pectoris NSTEMI-ACS) is common and is associated with a high mortality. In addition to 12-channel echocardiograph (ECG) assessment, measurement of cardiac troponins I and T are important for risk stratification and diagnosis. The introduction of high-sensitivity cardiac troponin assays and their implementation into clinical practice has influenced risk stratification and treatment of these patients. Additional diagnostic validation must supplement routine clinical chemistry testing following the initial measurement to distinguish between different possible causes of troponin elevation above the 99th percentile. The time point for the additional troponin measurement depends on the different protocols and troponin assays and is stipulated in the current guidelines. The use of both 1‑hour and 3‑hour protocols together with the clinical presentation and work-up of possible differential diagnoses provide optimal care of patients. Patients who test positive for troponin dynamics should undergo invasive diagnostics and treatment within 24 h of presentation and within 2 h is recommended for unstable patients. Clopidogrel is indicated only in patients requiring oral anticoagulation.
- Published
- 2017
- Full Text
- View/download PDF
21. [Computed tomography in patients with chronic stable angina : Fractional flow reserve measurement].
- Author
-
Renker M, Schoepf UJ, Becher T, Krampulz N, Kim W, Rolf A, Möllmann H, Hamm CW, Henzler T, Borggrefe M, Akin I, and Baumann S
- Subjects
- Evidence-Based Medicine, Humans, Reproducibility of Results, Sensitivity and Specificity, Angina, Stable diagnosis, Angina, Stable physiopathology, Blood Flow Velocity, Computed Tomography Angiography methods, Coronary Angiography methods, Fractional Flow Reserve, Myocardial
- Abstract
Coronary computed tomography angiography (cCTA) has been established for the non-invasive diagnosis of coronary artery disease (CAD). Previous studies demonstrated the high diagnostic accuracy of cCTA, particularly for ruling out CAD. As a known limitation of cCTA a large number of visually significant coronary stenoses are found to be hemodynamically not relevant by invasive fractional flow reserve (FFR). CT-based FFR (CT-FFR) builds on recent advances in computational fluid dynamics and image simulation techniques. Along with CT myocardial perfusion imaging, CT-FFR is a promising approach towards a more accurate estimation of the hemodynamic relevance of coronary artery stenoses. CT-FFR is derived from regular CT datasets without additional image acquisitions, contrast material, or medication. Two CT-FFR techniques can be differentiated. The initial method requires external use of supercomputers and has gained approval for clinical use in the USA. Furthermore, a prototype-software has been introduced which is less computationally demanding via integration of reduced-order models for on-site calculation of CT-FFR. The present article reviews these methods in the context of available study results and meta-analyses. Furthermore, limitations and future concepts of CT-FFR are discussed.
- Published
- 2017
- Full Text
- View/download PDF
22. "Full bioresorbable jacket": a new era has begun.
- Author
-
Dörr O, Liebetrau C, Hecker F, Wiebe J, Möllmann H, Hamm C, and Nef H
- Subjects
- Aged, Equipment Failure Analysis, Humans, Male, Prosthesis Design, Radiography, Treatment Outcome, Absorbable Implants, Blood Vessel Prosthesis, Coronary Stenosis diagnostic imaging, Coronary Stenosis therapy, Drug-Eluting Stents
- Published
- 2015
- Full Text
- View/download PDF
23. [ESC/EACTS guidelines on myocardial revascularization : Amendments 2014].
- Author
-
Nef H, Renker M, and Hamm CW
- Subjects
- Europe, Humans, Cardiology standards, Coronary Artery Bypass standards, Coronary Artery Disease diagnosis, Coronary Artery Disease surgery, Diagnostic Techniques, Cardiovascular standards, Patient Selection, Percutaneous Coronary Intervention standards
- Abstract
One of the most important treatment principles in interventional cardiology relies on myocardial revascularization by percutaneous coronary intervention (PCI) or surgical placement of coronary artery bypass grafts (CABG). However, in order to apply these principles effectively, it is important to identify patients who require revascularization. Consequently, the appropriate method has to be selected to effectively restore blood flow. Patients will only benefit from the interventional or surgical procedures when those revascularization measures that can cause more harm than good are avoided. In the new European Society of Cardiology and European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines on myocardial revascularization some new aspects will be addressed.
- Published
- 2014
- Full Text
- View/download PDF
24. [Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].
- Author
-
Bauer T and Hamm C
- Subjects
- Drug Therapy, Combination methods, Evidence-Based Medicine, Humans, Thrombosis etiology, Treatment Outcome, Acute Coronary Syndrome complications, Acute Coronary Syndrome drug therapy, Aspirin administration & dosage, Coronary Artery Bypass adverse effects, Emergency Medical Services methods, Percutaneous Coronary Intervention adverse effects, Platelet Aggregation Inhibitors administration & dosage, Thrombosis prevention & control
- Abstract
In most cases of ST segment elevation myocardial infarction (STEMI) a major coronary vessel is occluded by a thrombus. This is why early and effective antiplatelet therapy plays a key role. The current guidelines recommend the administration of dual antiplatelet therapy as early as possible. Despite the lack of convincing clinical evidence, prehospital administration appears reasonable, primarily because of pharmacokinetic considerations. Ticagrelor should be preferentially administered because the largest amount of evidence is available and it appears to be safe. In high-risk patients undergoing transfer to a catheterization laboratory, upstream use of a glycoprotein (GP) IIb/IIIa receptor antagonist (tirofiban) may be considered. Acute coronary syndrome without ST segment elevation (NSTE-ACS) represents a clinically heterogeneous group. Current guidelines recommend that antiplatelet therapy should be initiated as early as possible when the diagnosis of NSTE-ACS is made. If there is high clinical suspicion of NSTE-ACS acetylsalicylic acid (ASA) should be given before hospital admission. In high-risk patients prehospital administration of ticagrelor may be considered.
- Published
- 2014
- Full Text
- View/download PDF
25. [Procedural aspects in primary PCI: arterial access, stent selection, thrombectomy and treatment of non-culprit lesions].
- Author
-
Boeder NF, Hamm CW, and Nef HM
- Subjects
- Combined Modality Therapy instrumentation, Combined Modality Therapy methods, Coronary Stenosis complications, Humans, Myocardial Infarction etiology, Percutaneous Coronary Intervention methods, Thrombectomy methods, Blood Vessel Prosthesis, Coronary Stenosis surgery, Myocardial Infarction surgery, Percutaneous Coronary Intervention instrumentation, Prosthesis Fitting methods, Stents, Thrombectomy instrumentation
- Abstract
Acute myocardial infarction was one of the most common causes of death in Germany in 2011. According to the guidelines of the European Society for Cardiology, systemic fibrinolysis and primary percutaneous coronary intervention (PCI) are the methods of choice for acute treatment. Primary PCI should be given priority due to its superiority. The transradial access should be preferred due to the lower bleeding complication rate. In the selection of stents the new generation of drug-eluting stents (DES) are superior to the first generation of bare metal stents (BMS). It has now been demonstrated that the incident rates of DES (e.g. mortality, target vessel revascularization, early and late stent thrombosis and myocardial infarction) are significantly lower. For bioresorbable scaffolds (BRS) long-term results for the use in treatment of ST-elevation myocardial infarction (STEMI) are not yet available but initial results are very promising. However, the selection of a stent needs to be done on an individual basis in order to do justice to all aspects. Data with respect to thrombectomy in acute treatment are heterogeneous. Currently, a thorough consideration of all aspects is necessary because thrombus aspiration can also be associated with an increased rate of incidents. In a state of hemodynamic stability only so-called culprit lesions should currently be treated with a stent. Elective interventions on further stenoses should be carried out after consideration of individual factors and if necessary evaluation of the hemodynamic relevance.
- Published
- 2014
- Full Text
- View/download PDF
26. [Myocardial revascularization].
- Author
-
Möllmann H, Szardien S, Kempfert J, Nef H, Liebetrau C, Walther T, and Hamm C
- Subjects
- Coronary Artery Disease complications, Humans, Treatment Outcome, Blood Vessel Prosthesis adverse effects, Coronary Artery Disease surgery, Graft Occlusion, Vascular etiology, Graft Occlusion, Vascular prevention & control, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Stents adverse effects
- Abstract
Coronary artery disease (CAD) is a leading cause of morbidity and mortality in western countries and is of significant socio-economic importance due to its increasing prevalence. Until percutaneous coronary interventions (PCI) were established, CAD could only be treated by surgical revascularization or pharmacological therapy. In-stent restenosis remains a major problem after stent implantation. However, the use of new materials and stent coatings have led to a significant reduction in in-stent restenosis. Thus, surgical revascularization and PCI are currently of equal value for the treatment of CAD. The decision-making for PCI or surgical revascularization depends on various factors such as number of diseased vessels, complexity of the coronary stenoses, concomitant diseases, and the patient's general condition. The therapeutic regime of every patient should be adjusted to the recommendations of the European and German Society for Cardiology, while controversial and complex cases should be discussed in an interdisciplinary case conference ("heart team").
- Published
- 2013
- Full Text
- View/download PDF
27. [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].
- Author
-
Madlener K and Hamm C
- Subjects
- Administration, Oral, Anticoagulants adverse effects, Humans, Anticoagulants administration & dosage, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Stroke etiology, Stroke prevention & control, Vitamin K antagonists & inhibitors
- Abstract
Two novel oral anticoagulants, namely the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitor rivaroxaban, have recently been approved for treatment of atrial fibrillation. They differ in many ways from vitamin K antagonists, including rapid onset of action, shorter half-life, fewer drug-drug interactions, lack of a need for monitoring and no need for titration or dose adjustments. Commonly available global coagulation time assessments (e.g. prothrombin time and activated partial thromboplastin time) are highly influenced by rivaroxaban and dabigatran but these assays are relatively insensitive. Ideally these anticoagulant agents would be assessable using a sensitive and standardized test with a linear dose-response curve. Optimized assays are currently under investigation and may quantify the anticoagulant effect. At present the therapeutic ranges for dose adjustment have not yet been established.
- Published
- 2012
- Full Text
- View/download PDF
28. [Historical and current pathophysiological concepts of stress (Tako-Tsubo) cardiomyopathy].
- Author
-
Szardien S, Möllmann H, Elsässer A, Hamm CW, and Nef HM
- Subjects
- Animals, Female, Humans, Male, Catecholamines blood, Heart Ventricles physiopathology, Models, Cardiovascular, Myocardial Contraction, Receptors, Adrenergic, beta metabolism, Takotsubo Cardiomyopathy physiopathology
- Abstract
Tako-Tsubo cardiomyopathy (TTC), also referred to as stress cardiomyopathy (SCM), was first described in the 1990s and is characterized by transient left ventricular dysfunction. Its incidence represents 1-2% of all acute coronary syndromes (ACS). In most cases extreme emotional or physical stress precedes this syndrome. The majority of patients affected are postmenopausal women. Since its first description, various hypotheses regarding the pathophysiology of TTC have been discussed. From a historical perspective, coronary vasospasm has often been proposed as a possible cause of this disorder. However, reviews from numerous registries were able to demonstrate that coronary vasospasm plays only a minor role in the pathogenesis of TTC. Several groups showed disturbances in myocardial microcirculation and energy metabolism in the acute phase of TTC. Nevertheless, with regard to the data currently available, it cannot be differentiated whether these changes are the cause or rather the result of TTC. However, recent concepts include an excessive catecholamine overload and morphological changes which are unequivocally documented in TTC. The relation between elevated catecholamine levels and myocardial dysfunction analogous to TTC could be confirmed in animal experiments.In summary, it can be assumed that TTC is caused by an excessive cardiotoxic release of catecholamines. Ventricular dysfunction can be explained by increased numbers of β-adrenergic receptors in the apex, leading to greater vulnerability to catecholamine overload. Individual anatomical differences in the sympathoadrenergic system and distribution from β-adrenergic receptors are presumably responsible for the interindividual occurrence of wall motion abnormalities in TTC.
- Published
- 2010
- Full Text
- View/download PDF
29. [Redefinition of myocardial infarction--relevance of biomarkers].
- Author
-
Weber M and Hamm C
- Subjects
- Acute Coronary Syndrome blood, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome mortality, C-Reactive Protein metabolism, Germany, Humans, Myocardial Infarction blood, Myocardial Infarction mortality, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Practice Guidelines as Topic, Predictive Value of Tests, Prognosis, Troponin blood, Biomarkers blood, Myocardial Infarction diagnosis
- Abstract
Myocardial infarction (MI) as an acute and life-threatening complication of coronary heart disease is one of the most frequent causes of death in Germany. Therefore, diagnosis, risk stratification and treatment of acute MI are of great clinical relevance. Specific recommendations concerning diagnosis of acute MI can be found in current guidelines of the European Society of Cardiology (ESC) and the German Cardiac Society, as well as in a consensus document "Universal definition of myocardial infarction", which has been published at the end of 2007. Here, cardiac markers, namely cardiac troponins, play a central role as a criterion for the diagnosis of myocardial infarction. Moreover, cardiac troponins provide prognostic information and are of great value for risk stratification of patients. Measurement of creatine kinase CK-MB is an alternative to troponin measurement, but is only recommended, if troponins are not available. As a cutoff value for cardiac biomarkers the 99th percentile of a healthy reference population has been defined. However, assays that are used for routine testing require adequate precision. Besides established biomarkers, several novel markers have been evaluated in clinical studies in recent years. Especially B-type natriuretic peptides (BNP and NT-proBNP) and C-reactive protein (CRP) have gained great interest and sufficient data has been gathered, justifying clinical application of these novel markers. As a consequence, BNP/NT-proBNP and CRP are mentioned in the current guidelines of the ESC as appropriate biomarkers for risk stratification. The clinical relevance of other novel biomarkers remains uncertain and necessitates further studies.
- Published
- 2008
- Full Text
- View/download PDF
30. [Biomarkers for the evaluation of valvular aortic stenosis].
- Author
-
Weber M and Hamm C
- Subjects
- Aortic Valve Stenosis blood, Aortic Valve Stenosis epidemiology, Aortic Valve Stenosis mortality, Aortic Valve Stenosis therapy, Biomarkers, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Longitudinal Studies, Predictive Value of Tests, Prognosis, Severity of Illness Index, Statistics, Nonparametric, Time Factors, Treatment Outcome, Aortic Valve, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Natriuretic Peptide, Brain blood
- Abstract
Aortic valve diseases, namely aortic stenosis (AS) and aortic regurgitation (AR), are common in developed countries with AS being the most common valvular heart disease. Symptomatic status and echocardiography are the most important clinical parameters to confirm the diagnosis, to assess the severity and to monitor progression of AS. Aortic valve replacement (AVR) is indicated in symptomatic patients with severe AS, but in asymptomatic patients with severe AS there is an ongoing controversial discussion whether these patients should undergo AVR or should be treated conservatively. For patients with moderate AS, surgical treatment is generally not recommended, even though recent data suggest that the outcome of these patients is worse than commonly assumed.In several studies that included patients with valvular AS, an elevation of BNP and NT-proBNP serum concentrations related to disease severity has been reported (Figure 1). Consequently, in a longitudinal study it was found, that NT-proBNP concentrations decrease after successful surgical therapy but increase in conservatively treated patients with AS (Figure 2). These changes of NT-proBNP values over time were related to changes of the transvalvular pressure gradient (Figure 3). Furthermore, it has been demonstrated in clinical outcome studies that elevated NT-proBNP and BNP values, respectively, were associated with an unfavorable clinical course especially in patients who were treated conservatively (Figure 4).Thus, these results suggest that natriuretic peptides can be used as biomarkers for the diagnostic work-up of patients with AS and might be helpful to decide on the optimal timing of AVR (Table 1).
- Published
- 2006
- Full Text
- View/download PDF
31. [Risk stratification in acute coronary syndrome].
- Author
-
Goldmann BU and Hamm CW
- Subjects
- Abciximab, Acute Disease, Angina, Unstable blood, Angina, Unstable diagnosis, Angina, Unstable drug therapy, Antibodies, Monoclonal therapeutic use, Anticoagulants therapeutic use, Biomarkers, Clinical Trials as Topic, Coronary Disease blood, Coronary Disease drug therapy, Fibrinolytic Agents therapeutic use, Humans, Immunoglobulin Fab Fragments therapeutic use, Nadroparin therapeutic use, Platelet Aggregation Inhibitors therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Prognosis, Retrospective Studies, Risk Factors, Syndrome, Terminology as Topic, Tirofiban, Troponin I blood, Troponin T blood, Tyrosine therapeutic use, Coronary Disease diagnosis, Tyrosine analogs & derivatives
- Abstract
Background: The spectrum of symptoms of patients with active ischemic heart disease ranges from silent ischemia to acute myocardial infarction and the extent of myocardial damage from reversible myocardial injury to extensive necrosis. The term "acute coronary syndrome" comprises this continuum. In particular the evaluation of patients without ST-segment elevation is difficult, for clinical symptoms, ECG criteria and CK-MB measurements appear insufficient for appropriate risk stratification., Troponin Measurement: Serial measurements of either troponin T or I reliably detect minor myocardial damage in those patients, who are known to be at a higher risk for adverse cardiac events comparable to the risk of patients with acute myocardial infarction. Hence determination of troponins allow superior risk stratification contributing to early triage and therapeutic decision making. Without elevation of troponins the cardiac risk for death or myocardial infarction will not exceed 1%., Conclusion: Patients with elevated troponins should be early hospitalized and further evaluated in order to begin efficacious therapy as soon as possible. These patients represent a high-risk subgroup of patients clinically classified as unstable angina, who might benefit from potential antithrombotic treatment such as low-molecular weight heparin or glycoprotein IIb/IIIa antagonists without or with revascularization strategies.
- Published
- 2001
- Full Text
- View/download PDF
32. Potassium channel openers and blockers in coronary artery disease. Comparison to betablockers and calcium antagonists.
- Author
-
Mitrovic V, Oehm E, Thormann J, Pitschner H, and Hamm C
- Subjects
- Adrenergic beta-Antagonists administration & dosage, Adrenergic beta-Antagonists therapeutic use, Adult, Aged, Analysis of Variance, Angina Pectoris drug therapy, Anti-Arrhythmia Agents administration & dosage, Atenolol administration & dosage, Atenolol therapeutic use, Benzopyrans administration & dosage, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Calcium Channel Blockers administration & dosage, Calcium Channel Blockers therapeutic use, Cardiotonic Agents administration & dosage, Coronary Disease physiopathology, Cyclopropanes administration & dosage, Dihydropyridines administration & dosage, Electrocardiography, Exercise Test, Gallopamil administration & dosage, Gallopamil therapeutic use, Hemodynamics, Humans, Middle Aged, Myocardium metabolism, Oxygen Consumption, Propanolamines administration & dosage, Propanolamines therapeutic use, Time Factors, Vasodilator Agents administration & dosage, Anti-Arrhythmia Agents therapeutic use, Benzopyrans therapeutic use, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Cardiotonic Agents therapeutic use, Coronary Disease drug therapy, Cyclopropanes therapeutic use, Dihydropyridines therapeutic use, Potassium Channel Blockers, Potassium Channels agonists, Vasodilator Agents therapeutic use
- Abstract
Potassium channel openers and blockers, which belong to a novel class of vasodilator drugs and to the class of specific bradycardic substances, are potential new antianginal drugs. Experimental findings in vivo suggest that bimakalim is a new substance characterized as ATP-sensitive K+ channel openers, since it exerts preferential vasodilation of the collateral circulation of the coronary vasculature and both leads to increase blood flow to ischemic areas and to attenuate the ST segment elevation caused by regional ischemia in the canine heart. Opening of KATP increases the conductivity of potassium ions which results in hyperpolarization of smooth muscle membranes, thus producing vasodilation. Tedisamil is a new bradycardic agent proven to exert antiischemic and antiarrhythmic effects by blockade of the cellular cardiac repolarization K+ currents as well as of multiple neuronal and vascular K+ currents (Ito, Ik, and K+ATP). Using right heart catheterization and exercise tolerance tests, we investigated the hemodynamic, antiischemic and neurohumoral effects of bimakalim and tedisamil in patients with angiographically proven coronary artery disease, stable angina pectoris and reproducible ST segment depression during exercise. In 50 patients with coronary artery disease, the hemodynamic and antiischemic effects of a single oral dose bimakalim of 0.1 mg, 0.3 mg and 0.6 mg were compared to placebo. In a dose-finding baseline-controlled study, a comparable collective was examined for the effects of acute i.v. administration of tedisamil 0.1, 0.2, 0.3 and 0.4 mg/kg bw. A subgroup of 8 patients receiving 0.3 mg/kg bw tedisamil i.v. was compared with a similar group of 14 patients who had received esmolol (i.v. bolus of 500 micrograms/kg, maintenance dose 200 micrograms/kg/min) and gallopamil (initial dose 0.025 mg/kg, maintenance dose 0.0005 mg/kg/h) in a second intra-individual comparison. Furthermore, in 48 patients, short-term (6 days) effects of tedisamil, 2 times 100 mg orally, were compared to 2 times 50 mg atenolol treatment. With a single oral dose of bimakalim antianginal and/or antiischemic effects were lacking, increased doses, however, induced changes in hemodynamics typical of vasodilation, i.e., a significant decrease in systolic blood pressure and a secondary chronotropic response. In contrast to bimakalim, tedisamil produced antiischemic effects and was found to have favorable hemodynamic, neurohumoral and antiischemic effects in comparison to the betablocker esmolol and atenolol in patients with coronary artery disease. Tedisamil induced a dose-dependent decrease in both heart rate and the index of myocardial oxygen consumption associated with an improvement in ST segment depression. Tedisamil as well as esmolol and atenolol showed almost equipotent antiischemic effects at the doses administered. Compared with gallopamil, both tedisamil and esmolol were superior in their effects on myocardial oxygen consumption and ST segment depression, whereas plasma lactate concentrations were more reduced by tedisamil and gallopamil.
- Published
- 2000
- Full Text
- View/download PDF
33. [Rotational atherectomy: technique, indications, results].
- Author
-
Dill T and Hamm CW
- Subjects
- Angioplasty, Balloon, Coronary, Contraindications, Coronary Disease surgery, Humans, Atherectomy, Coronary instrumentation, Atherectomy, Coronary methods, Atherectomy, Coronary standards
- Abstract
Rotational atherectomy (Rotablation) represents one of the alternative devices to treat complex coronary artery stenoses. Rather than increasing luminal diameter by arterial stretching and plaque fracture as with balloon angioplasty, rotablation debulks atherosclerotic plaque with an abrasive diamond coated burr. The basic physical principle is differential cutting. It allows the advancing burr to selectively cut inelastic material while elastic tissue deflects away from the burr. 95% of the particles generated by the Rotablator are less than 5 microns. They are removed by the body's reticuloendothelial system. There are different strategies to perform a rotablation, regarding the number of burrs used and the final burr-to-artery ratio. An adjunctive PTCA is recommended without proof by randomized studies so far. The best indication for the Rotablator is the undilatable lesion. Lesion modification (debulking) as a method of improving vessel compliance seems to be also usefull in diffusely diseased and calcified vessels, as well as in aorto-ostial and angulated stenoses. The instent restenoses is a new indication. Randomized studies will have to proof if there is an advantage for rotablation compared to PTCA. Restenosis rates appear comparable to balloon angioplasty.
- Published
- 1997
- Full Text
- View/download PDF
34. Intravenous coronary angiography with dichromography using synchrotron radiation.
- Author
-
Hamm CW, Meinertz T, Dix WR, Rust C, Graeff W, Illing G, Lohmann M, Menk R, Reime B, Schildwächter L, Besch HJ, and Kupper W
- Subjects
- Animals, Dogs, Equipment Design, Humans, Sensitivity and Specificity, Angiography, Digital Subtraction instrumentation, Coronary Angiography instrumentation, Coronary Disease diagnostic imaging, Image Processing, Computer-Assisted instrumentation, Synchrotrons
- Abstract
Dichromography represents a digital subtraction angiography mode based on energy substraction which allows imaging of fast moving subjects like the heart. For logarithmic subtraction 2 images with X-rays just below and above the iodine K-edge (33.17 keV) are simultaneously obtained in a line scan mode. Monochromatic X-rays of sufficient intensity to visualize coronary arteries of 1 mm diameter with extremely low iodine concentrations (1 mg/cm2) after venous injection is only provided by synchrotron radiation. The system NIKOS (non-invasive coronary arteriography with synchrotron radiation) at the Deutsches Elektronen Synchrotron (DESY) consists of 6 components: a wiggler, a monochromator, a safety system, a scanning device, a detector and a computer system. After experimental studies in dogs patients are imaged since 1990. Initial results demonstrate feasibility and safety of synchrotron radiation coronary angiography. Large scale studies are designed to further evaluate sensitivity and specificity. When compact synchrotron radiation sources become available, this technique could be used for follow-up studies and for evaluation of certain high coronary risk populations.
- Published
- 1996
35. -New perspectives in therapy of unstable angina-.
- Author
-
Hamm CW
- Subjects
- Angina, Unstable blood, Anticoagulants adverse effects, Clinical Trials as Topic, Coronary Thrombosis blood, Dose-Response Relationship, Drug, Drug Therapy, Combination, Heparin adverse effects, Humans, Platelet Aggregation Inhibitors adverse effects, Treatment Outcome, Angina, Unstable drug therapy, Anticoagulants therapeutic use, Coronary Thrombosis drug therapy, Heparin therapeutic use, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Unstable angina is a critical phase of coronary heart disease with high risk of myocardial infarction and death. Recently, major advances have been made concerning therapeutic management and risk stratification., Pathogenetic Mechanisms: Plaque rupture followed by local thrombus formation is the underlying mechanism for the majority of patients with unstable angina. The process that leads to plaque rupture is a complex sequence of events which includes local inflammatory activity. Rapid progression and vasospasm play a pathogenetic role only in a few patients. NEW THERAPEUTIC STRATEGIES: Pain relief is frequently successfully achieved by intravenous nitrates combined with betablockers. Calciumantagonists may be added, if angina persists. Prognostic improvement is achieved by platelet inhibitors, like acetylsalicylic acid or ticlopidine. In patients with persisting angina at rest platelet inhibitors should be combined with high-dose heparin. Thrombolytics have no advantage and should not be given without electrocardiographic evidence of myocardial infarction. The potential additional benefit of new glycoprotein IIb/IIIa receptor inhibitors or more potent anti-thrombins, like hirudin or hirulog, need to be further evaluated in larger trials. THERAPY CONTROL: The detection of minor myocardial cell injury by measurements of new cardiac markers like troponin T is associated with an unfavourable outcome. Troponin T may therefore serve as parameter for risk stratification in emergency rooms and control therapeutic regimens.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.